Showing results (101-110 of 194) with videos related to
Sort By:
Pageof 20
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 27, 2015
Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR)Scott R Evans, Daniel Rubin, Dean Follmann, et al.Plos One|April 13, 2012
Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccinationCheng Cheng, Lingshu Wang, LingShu Wang, et al.Clinical Trials (London, England)|July 18, 2020
Endpoints for randomized controlled clinical trials for COVID-19 treatmentsLori E Dodd, Dean Follmann, Jing Wang, et al.Medrxiv : the Preprint Server for Health Sciences|May 7, 2025
Continuous Infusion of the CXCR4 Antagonist Plerixafor for WHIM SyndromeDavid H McDermott, Shamik Majumdar, Daniel Velez, et al.Journal of Virological Methods|February 27, 2018
Use of the Filovirus Animal Non-Clinical Group (FANG) Ebola virus immuno-assay requires fewer study participants to power a study than the Alpha Diagnostic International assayJames Logue, Kaylie Tuznik, Dean Follmann, et al.Journal of Virology|November 20, 2009
Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variablesNicole A Doria-Rose, Rachel M Klein, Marcus G Daniels, et al.Blood|March 15, 2011
Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8+ T-cell exhaustion in HIV infectionTakuya Yamamoto, David A Price, Joseph P Casazza, et al.Science Translational Medicine|November 29, 2019
A meta-analysis of clinical studies conducted during the West Africa Ebola virus disease outbreak confirms the need for randomized control groupsLori E Dodd, Dean Follmann, Michael Proschan, et al.Annals of Internal Medicine|July 5, 2022
Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical TrialDean Follmann, Holly E Janes, Olive D Buhule, et al.Biostatistics (Oxford, England)|June 22, 2025
A surrogate endpoint-based provisional approval causal roadmap, illustrated by vaccine developmentPeter B Gilbert, James Peng, Larry Han, et al.Pageof 20